earnings
confidence high
sentiment neutral
materiality 0.65
Anebulo reports Q2 FY2025 net loss $2.5M ($0.09/sh); secures $15M private placement; FDA supports pediatric plan
Anebulo Pharmaceuticals, Inc.
2025-Q2 EPS
reported -$0.17
vs consensus -$0.08
▼ miss
(-108.3%)
- Net loss for Q2 FY2025 (Dec 31, 2024) was $2.5M, or $0.09 per share, compared to $2.7M ($0.11) in prior year.
- Cash and equivalents $15.0M as of Dec 31, 2024; additional $3M available under amended loan.
- FDA acknowledged unmet need for pediatric cannabis toxicity treatment; Phase 1 SAD study of IV selonabant expected in H1 2025.
- Closed $15M private placement with 22NW Fund, issuing 15.2M shares.
- Amended loan with 22NW and JFL, reducing max to $3M and removing securitization.